Home / Fact sheets / Population fact sheet

Country fact sheet: Finland

Population

- Total population: 5 495 303
- Female population: 2 789 146
- Male population: 2 706 157
The World Bank (2016)

Health Expenditure

- Total per capita (US$): 4 005.5
- Out-of-pocket (% of total expenditure on health): 19.9
World Health Organization (2015)

Human Development Index

- HDI: 0.895
- Category: Very high
UNDP Human Development Report (2015)

Geography

Life Expectancy at Birth

- Total population (years): 81.8
- Female population (years): 84.7
- Male population (years): 79.0
The World Bank (2016)

Cancer Burden

- Overall cancer incidence (rate per 100 000 persons per year): 266.3
- Overall cancer mortality (rate per 100 000 persons per year): 83.3
- Most common cancer site by incidence for females (rate per 100 000 persons per year): Breast (89.5)
- Most common cancer site by mortality for females (rate per 100 000 persons per year): Breast (11.3)
- Most common cancer site by incidence for males (rate per 100 000 persons per year): Prostate (71.6)
- Most common cancer site by mortality for males (rate per 100 000 persons per year): Lung (20.8)
- GLOBOCAN 2018 population fact sheet
GLOBOCAN (2018)

BREAST CANCER SCREENING PROGRAMME

Last updated year for qualitative data: 2016
Source of data: Report (EU Report 2017)
Last updated year for quantitative data: 2012
Source of data: Report (EU Report 2017)

Screening protocol

Year published/updated:
Screening test used: 1
Target age (min-max) and screening interval [months] for each test: Mammography
(50-69 years / [24 months] )

Programme status and organization

Dedicated person/team to coordinate the programme:
Budget line for screening programme:
Documented cancer screening policy:
Nature of documentation of the policy: Official recommendation
Program introduction was preceded by a pilot:
Year program was initiated: 1987
Screening tests provided free of charge:
Diagnostic tests provided free of charge:
Treatment services provided free of charge:

Information system/Data collection

Data type collected by the programme: Individual
The information system collects data outside the program (opportunistic screening/private sector):
Cancer screening registries covering the entire country/region:
Cancer screening data is linked with Population-based cancer registry:

Invitation to screening and further assessment

Method of identification of eligible individuals: From population data
Source of population data: Population register
Annual target for screening coverage:
Invitations to eligible population: For the entire target population
Method of invitation: letter
Screen positive individuals actively invited for further assessment:
Individuals with a precancer or cancer diagnosis actively contacted:
Program collects data on the treatment of precancer/cancers:

Programme monitoring and quality assurance (QA)

Documented standard operating procedure/policy for QA:
Responsible person/team for QA:
Documented performance indicators and their reference standards to assess the programme:
Evaluation reports are prepared and published:

Cancer Screening programme status

Nature of cancer screening programme: Population-based
Current status of implementation (applicable only for population-based programmes): Roll-out completed
Cancer screening programme population based for selected populations:

Performance indicators

Target age and regional limitation if applicable: 50-69 years
Invitation coverage (%): 91.6
Examination coverage (%): 76.1
Participation rate (%): 83
Completeness of data related to screening results (%): 100
Completeness of data related to further assessment results (%): 98.3
Further assessment rate (%): 2.6
Further assessment participation rate (%): 99.9
Detection rate of CIS and invasive (x 1000): 5.67
Detection rate of invasive cancer (x 1000): 0.71
Positive predictive value of further assessment to detect CIS and invasive (%): 21.8
Proportion of total carcinomas which are CIS (%): 12.5
Benign surgical biopsy rate (x 1000): 1.18
More quantitative data (2012)



CERVICAL CANCER SCREENING PROGRAMME

Last updated year for qualitative data: 2016
Source of data: Report (EU Report 2017)
Last updated year for quantitative data: 2012
Source of data: Report (EU Report 2017)

Screening protocol

Year published/updated:
Screening test used: 1
Target age (min-max) and screening interval [months] for each test: Cytology
(30-64 years / [60 months] )
Triaging test used: None
"screen and treat" included in the protocol:

Programme status and organization

Dedicated person/team to coordinate the programme:
Budget line for screening programme:
Documented cancer screening policy:
Nature of documentation of the policy: Official recommendation
Program introduction was preceded by a pilot:
Year program was initiated: 1963
Screening tests provided free of charge:
Diagnostic tests provided free of charge:
Treatment services provided free of charge:

Information system/Data collection

Data type collected by the programme: Individual
The information system collects data outside the program (opportunistic screening/private sector):
Cancer screening registries covering the entire country/region:
Cancer screening data is linked with population-based cancer registry:

Invitation to screening and further assessment

Method of identification of eligible individuals: From population data
Source of population data: Population register
Annual target for screening coverage:
Invitations to eligible population: For the entire target population
Screening kit included with the invitation:
Method of invitation: letter
Screen positive individuals actively invited for further assessment:
Individuals with a precancer or cancer diagnosis actively contacted:
Program collects data on the treatment of precancer/cancers:

Programme monitoring and quality assurance (QA)

Documented standard operating procedure/policy for QA:
Responsible person/team for QA:
Documented performance indicators and their reference standards to assess the programme:
Evaluation reports are prepared and published:

Cancer Screening programme status

Nature of cancer screening programme: Population-based
Current status of implementation: Roll-out completed
Cancer screening programme population based for selected populations/regions:

Performance indicators

Target age and regional limitation if applicable: 30-59 years
Invitation coverage (%): 97.9
Examination coverage (invitation cohort) (%): 64.4
Examination coverage (tests in the index-year) (%):
Participation rate (%): 65.8
Completeness of data related to screening test results (%): 100
Completeness of data related to further assessment results (%): 95.5
Colposcopy referral rate (%): 1.0
Colposcopy participation rate (%): 98.8
Detection rate of CIN2+ (x 1000): 2.95
Detection rate of CIN3+ (x 1000): 1.59
Positive Predictive Value of abnormal screening test to detect CIN2+ (x 1000): 31.2
Positive Predictive Value of CIN3+ (x 1000): 31.2
More quantitative data (2012)



COLORECTAL CANCER SCREENING PROGRAMME

Last updated year for qualitative data: 2014
Source of data: Report (EU Report 2017)
Last updated year for quantitative data: 2014
Source of data: No source

Screening protocol

Year published/updated:
Screening test used: 1
Target age (min-max) and screening interval [months] for each test: gFOBT: (60-69 years / [24 months] )

Programme status and organization

Dedicated person/team to coordinate the programme:
Budget line for screening programme:
Documented cancer screening policy:
Nature of documentation of the policy: Official recommendation
Program introduction was preceded by a pilot:
Year program was initiated: 2004
Screening tests provided free of charge:
Diagnostic tests provided free of charge:
Treatment services provided free of charge:

Information system/Data collection

Data type collected by the programme: Individual
The information system collects data outside the program (opportunistic screening/private sector):
Cancer screening registries covering the entire country/region:
Cancer screening data is linked with population-based cancer registry:

Invitation to screening and further assessment

Method of identification of eligible individuals: From population data
Source of population data: Population register
Annual target for screening coverage:
Invitations to eligible population: For the entire target population
Method of invitation: letter
Screen positive individuals actively invited for further assessment:
Individuals with a precancer or cancer diagnosis actively contacted:
Program collects data on the treatment of precancer/cancers:

Programme monitoring and quality assurance (QA)

Documented standard operating procedure/policy for QA:
Responsible person/team for QA:
Documented performance indicators and their reference standards to assess the programme:
Evaluation reports are prepared and published:

Cancer Screening programme status

Nature of cancer screening programme: Population-based
Current status of implementation (applicable only for population-based programmes): Pilot
Cancer screening programme population based for selected populations:

Performance indicators

FIT gFOBT sigmoidoscopy Colonoscopy
Target age and regional limitation if applicable: 50-74
Invitation coverage (%): 24.7
Examination coverage (%): 16.5
Participation rate (%): 66.6
Completeness of data related to screening results (%): 99.8
Completeness of data related to information about attendance to colonoscopy assessment (%): 99.2
Completeness of data related to histology result (%): 100.1
Screen positivity (indication for follow-up colonoscopy) rate (%) : 2.9
Follow-up colonoscopy participation rate (%): 80.0
Completion rate follow-up colonoscopy (%):
Detection rate of adenomas (x 1000): 6.9
Detection rate of advanced adenomas (x 1000): 0.9
Detection rate of colorectal cancers (x 1000): 0.8
Positive Predictive Value of further assessment to detect adenomas (%): 30.1
Positive Predictive Value of further assessment to detect advanced adenomas (%): 4.1
Positive Predictive Value of further assessment to detect colorectal cancers (%): 3.8
More quantitative data for gFOBT (Male - 2014)
More quantitative data for gFOBT (Women - 2014)